Zenas BioPharma, Inc. (ZBIO) stock
ZBIONasdaqPharmaceutical PreparationsFiscal year ends December 31
Số liệu tài chính tới Q3 năm tài chính 2026, quý kết thúc ngày Sep 30, 2026Last filing: 10-Q on Nov 5, 2026Score 1/30
$27.93−0.08 (-0.29%)
Close on Nov 16, 2026Market cap $1.82BP/E –Yield –
Zenas BioPharma operating margin
Operating margin is operating income as a percentage of revenue.
Zenas BioPharma's operating margin for the twelve months ending Dec 31, 2025 was -3830.6%. For fiscal 2025 it was -3830.6%, against -3277.8% the year before.
Annual operating margin
| Period | Period end | Value | Change (pts) |
|---|---|---|---|
| FY2025 | Dec 31, 2025 | -3830.6% | −552.8 |
| FY2024 | Dec 31, 2024 | -3277.8% | −3203.5 |
| FY2023 | Dec 31, 2023 | -74.3% | – |
Quarterly operating margin
Change is against the same quarter a year earlier.
| Period | Period end | Value | Change (pts) |
|---|---|---|---|
| Q3 FY2026 | Sep 30, 2026 | -1034.1% | −1105.3 |
| Q2 FY2026 | Jun 30, 2026 | -10765.9% | – |
| Q1 FY2025 | Mar 31, 2025 | -373.3% | – |
| Q4 FY2024 | Dec 31, 2024 | -1112.5% | – |
| Q3 FY2023 | Sep 30, 2023 | 71.2% | – |
See a number that looks wrong?